Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) has announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., recently obtained a drug clinical trial approval notice from the National Medical Products Administration for Adebeli Monoclonal Antibody Injection, with clinical trials scheduled to commence in the near future. In accordance with the Drug Administration Law of the People's Republic of China and relevant regulations, the Adebeli Monoclonal Antibody Injection application, accepted on December 8, 2025, has been reviewed and deemed to meet the requirements for drug registration, granting approval for the initiation of clinical trials. The specific trial is a randomized, double-blind, multicenter Phase III clinical study evaluating Adebeli Monoclonal Antibody (SHR-1316) combined with Tegafur, Gimeracil, and Oteracil Potassium (S-1) and Oxaliplatin (SOX) versus a placebo combined with S-1 and Oxaliplatin for the perioperative treatment of resectable gastric or gastroesophageal junction cancer.